Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9402-27-Q-9102

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

San Antonio, Texas, UNITED STATES

SourceSAM
The Department of Defense, through the Defense Health Agency (DHA), has issued a solicitation (Procurement Identifier: HT9402-27-Q-9102) seeking quotations for pharmaceutical agents to support the Department of War’s (DoW) Uniform Formulary (UF) and the Uniform Formulary Additional Discount Program (UF ADP). This procurement is mandated by 10 U.S.C. § 1074g and its implementing regulation (32 CFR Section 199.21), which require the establishment of an effective, efficient, and integrated pharmacy benefits program for the Military Health System (MHS). The program’s primary objective is to ensure the availability of clinically and cost-effective pharmaceutical agents for military beneficiaries. The scope of this solicitation encompasses the acquisition of pharmaceutical agents within specific drug classes identified for potential placement on the DoW Uniform Formulary. The process is guided by recommendations from the DoW Pharmacy and Therapeutics (P&T) Committee, which evaluates the relative clinical and cost effectiveness of agents within each therapeutic class. The outcome of this process determines the classification of each agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF), which in turn impacts cost-sharing and access for beneficiaries. For the February 2027 P&T Committee meeting, the following newly approved drugs will be reviewed for potential inclusion: - Atebrioz (Skeletal Muscle Relaxants and Combinations) - Emcitate (Thyroid and Antithyroid Agents) - Hibsago (Hepatitis B Agents) - Juvmo (Parkinson’s Agents) - Zegfrovy (Lung Cancer, EGFR+ NSCLC subclass) Interested pharmaceutical manufacturers are invited to submit quotations in response to the attached Request for Quotation (RFQ), which includes detailed instructions, deadlines, and appendices for both the UF Blanket Purchase Agreement (BPA) and the UF Additional Discount Program (ADP). The RFQ outlines the submission process, including the requirement to respond to clinical questions (Part 3.4) via email to the designated point of contact by the specified deadline (Part 2.3.2). A pre-quotation teleconference is scheduled for November 17, 2026, with details provided in Part 2.4 of the RFQ. The place of performance for this procurement is San Antonio, Texas. The applicable North American Industry Classification System (NAICS) code is 325412 (Pharmaceutical Preparation Manufacturing), and the Product Service Code is 6505 (Drugs and Biologicals). This opportunity is open to qualified entities capable of manufacturing and supplying the specified pharmaceutical agents in accordance with federal requirements. The contracting entity for this solicitation is the Defense Health Agency, a federal office under the Department of Defense. The primary point of contact for this procurement is Stephanie Erpelding ([email protected]), with Julianne Canaley ([email protected]) listed as the secondary contact. Contractors considering this opportunity should review the attached RFQ and associated documents for comprehensive requirements, submission instructions, and evaluation criteria. The solicitation remains active, with a response deadline of November 30, 2026, at 18:11. All relevant documents and updates are accessible via the official SAM.gov opportunity page (https://sam.gov/opp/fe90f9ebb8f44bb798775e53a965c877/view). This procurement represents a significant opportunity for pharmaceutical manufacturers to participate in the Military Health System’s integrated pharmacy benefits program, supporting the health and readiness of military personnel and their families.
Documents9